このエントリーをはてなブックマークに追加
ID 30795
JaLCDOI
FullText URL
Author
Matsuo, Keisuke
Ueoka, Hiroshi
Shibayama, Takuo
Matsumura, Tadashi
Takigawa, Nagio
Hiraki, Shunkichi
Harada, Mine
Abstract

We have established an Adriamycin (ADM) -resistant small cell lung cancer (SCLC) cell line, SBC-3/ADM100, which shows multifactorial mechanisms of resistance to ADM, such as overexpression of P-glycoprotein, an enhanced detoxifying system and a decrease in topoisomerase II activity. In the present study, we confirmed that SBC-3/ADM 100 showed collateral sensitivity to methotrexate and TNP-351, a new antifolate, though this cell line showed a typical multidrug resistance (MDR) pattern. We also demonstrated a faster uptake and higher accumulation (1.3-fold) of TNP-351 in the SBC-3/ADM100 cells than those in the parent SBC-3 cells. These results explain one of the mechanisms for collateral sensitivity in the resistant cells. Furthermore, this cell line was found to have no cross-resistance to edatrexate and minimal cross-resistance to trimetrexate, 254-S (cisplatin analog), 5-fluorouracil and 4-hydroperoxyifosfamide. These drugs will have clinical importance in patients with SCLC who were previously treated with an ADM-containing regimen. Thus, antifolates, especially TNP-351 and edatrexate, can be expected to eradicate residual multidrug resistant SCLC cells selected by ADM.

Keywords
Adriamycin-resistant cell line
antifolates
small cell lung cancer
Amo Type
Article
Published Date
1997-06
Publication Title
Acta Medica Okayama
Volume
volume51
Issue
issue3
Publisher
Okayama University Medical School
Start Page
121
End Page
127
ISSN
0386-300X
NCID
AA00508441
Content Type
Journal Article
language
英語
File Version
publisher
Refereed
True
PubMed ID
Web of Science KeyUT